Selpercatinib Extends PFS in First-line RET-Positive NSCLC :

A randomized trial found that selpercatinib improved PFS by more than two-fold, but overall survival data remain immature.

Related Keywords

, Eli Lilly , Fung Loong , European Society For Medical Oncology , Chinese University Of Hong Kong , Herbert Ho Fung Loong , Chinese University , Hong Kong , Medical Oncology , New England Journal , Non Small Cell Lung Cancer , Nsclc , Lung Cancer , Ung Carcinoma , Ancer Lung , Brain Metastasis , Metastatic Brain Tumor , Metastasis , Malignant Head And Neck Neoplasm , Brain , Malignant Secondary Lung Neoplasm , Etastasis Lung , Hepatocellular Carcinoma , Liver Cancer , Dcc , Hepatocellular Cancer , Ancer Liver , Ancer Hepatocellular , Aminotransferase , Dust , Liver Enzymes , Liver Studies , Olt , Genomics , Reno ,